Compare Abbott Laboratories (ABT) vs Five9 Inc (FIVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Five9 Inc — how do they compare? Abbott Laboratories trades at $95.37 (market cap $166.94B), while Five9 Inc trades at $24.16 (market cap $1.91B). The key difference: Abbott Laboratories is far larger — about 87.4× Five9 Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| ABT | FIVN | |
|---|---|---|
Market Cap | $166.94B | $1.91B |
Sector | Health | Technology |
52-Week High | $136.62 | $29.16 |
52-Week Low | $82.57 | $13.61 |
Enterprise Value | $193.69B | $1.99B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Five9 (FIVN) trades at $24.99, up 6.59% today, showing strong momentum after consistently beating earnings estimates. The stock maintains bullish technical signals with moving averages supporting upward trends, though RSI levels indicate potential overbought conditions. Revenue growth has accelerated from $779M in 2022 to $1.15B in 2025, with the company achieving profitability for the first time in 2025 with $39M net income. Recent leadership appointments and AI product launches signal continued innovation in the CX platform space.
The outlook remains positive with 61% analyst buy ratings and a $27 consensus target offering 8% upside. Key catalysts include sustained revenue growth and margin expansion, while risks involve ongoing fiduciary investigations and competitive pressures in the cloud contact center market. The stock's premium valuation (P/E 37.1) requires continued execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
